Grant Zeng, CFA
Contributor since: 2011
Company: Zacks Investment Research, Inc.
Posts
Celator: A Unique Drug Ratio Technology Company For Cancer
Arrowhead: There Is Still Room For Further Share Price Appreciation
Mirati: An US Company With Targeted Therapy In Focus
Phase II Data Of ADXS-HPV For Cervical Cancer Are Encouraging
GALE Is Making Progresses In Its Three Clinical Programs
NWBO: Great Progress Made To Advance DCVax-L And DCVax-Direct
Immunovaccine Is On Track To Advance Clinical Programs
ATOS: Any Retreat In Share Price Should Provide A Good Entry Opportunity
TKMR Is On Track To Advance TKM-Ebola Program
2013 Will Be A Banner Year For GeoVax
Distribution Agreement With Millennium HealthCare Will Boost Atossa Topline For 2013
GeoVax Is On Track To Advance Its HIV/AIDS Vaccine Programs In 2013
The FDA Letter Won't Impact Atossa’S Business Much
APDN: A Unique Anti-counterfeit Company Poised To Resume Growth In Second Half Of 2013
Bio-Path Shares Are Attractive Now
Current Decline In Share Price Is An Opportunity To Accumulate Shares
Galena Biopharma: Clinical Programs Remain On Track And Valuation Is Attractive
NeoGenomics Is Poised To Grow Further In 2013
Galena On Track To Advance NeuVax
Pressure BioSciences (PBIO), One Of The Most Undervalued Biotech Companies
Immunovaccine Is Making Progress In Advancing Its Clinical Programs
Novelos Is Advancing Three Candidates Based On Its Unique Diapeutic Platform
MethylGene Reports Encouraging Clinical And Preclinical Data
PBIO Continues To Move In A Positive Direction
Novelos' Initial Data From LIGHT Phase I/II Trial Are Very Encouraging
MethylGene: Initiating With An Outperform
Bio-Path Continues To Make Progress
Further Progress Made For DCVax-L Brain Cancer Clinical Trial
What Happened To Access Pharma In The Last Two Days?
First Cohort Of HOT Phase Ib In Solid Tumor Completed
Strategic Collaboration Means Better Penetration In The Sample Preparation Market
Initial LIGHT Data From Phase I/II Trial Are Encouraging